Exagen (XGN) Stock Statistics & Valuation Metrics

Exagen has a market cap or net worth of $76.25M. The enterprise value is $57.93M.

Exagen has 17,898,098 shares outstanding. The number of shares has decreased by -2.65% in one year.

Exagen’s return on equity (ROE) is -1.58 and return on invested capital (ROIC) is -41.73%.

The current PE Ratio of Exagen is -4.94. Exagen’s PEG ratio is 0.13.

In the last 12 months, Exagen had revenue of 55.64M and earned -15.12M in profits. Earnings per share was -0.83.

In the last 12 months, operating cash flow was -13.28M and capital expenditures -515.00K, giving a free cash flow of -13.79M billion.

Exagen pays an annual dividend of ―, resulting in a dividend yield of ―

Exagen upcoming earnings date is May 5, 2025, TBA Not Confirmed.

Exagen as a current ratio of 2.70, with Debt / Equity ratio of 33.36%

In the past 12 months, Exagen has paid 12.00K in taxes.

Exagen EV to EBITDA ratio is -5.00, with an EV/FCF ratio of -4.04.

Exagen has $22.04M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$18.85M billion.

Gross margin is 59.51%, with operating margin of -24.51%, and net profit margin of -27.17%.

The average price target for Exagen is $6.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy